Dysmenorrhea Market

Market Overview:

The 7 major dysmenorrhea markets reached a value of US$ 10.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.44% during 2024-2034.

The dysmenorrhea market has been comprehensively analyzed in IMARC's new report titled "Dysmenorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dysmenorrhea is a medical condition characterized by painful menstrual periods. Some of the common indications of dysmenorrhea include cramping, lower abdominal pain, back pain, headache, nausea, vomiting, diarrhea, fatigue, etc. The pain can be intermittent or continuous and may start before or during menstruation. The severity of dysmenorrhea symptoms varies from woman to woman and month to month. Some women may also experience emotional indications, such as mood swings or irritability, during their menstrual period. The diagnosis of dysmenorrhea is typically made based on a woman's reported symptoms and medical history. A healthcare provider may ask about the timing and duration of menstrual pain, as well as the severity of indications and any associated factors, including nausea and fatigue. A physical exam is also conducted to check for any underlying medical conditions, such as pelvic inflammatory disease (PID), endometriosis, fibroids, etc., that may be contributing to the menstrual pain. In some cases, several imaging tests, including an ultrasound and MRI, may be suggested to further evaluate the reproductive organs.

The rising prevalence of various associated risk factors, including endometriosis, adenomyosis, fibroids, pelvic inflammatory disease (PID), cervical stenosis, ovarian cysts, etc., is primarily driving the dysmenorrhea market. In addition to this, the inflating utilization of intrauterine devices (IUDs), which can cause irritation and inflammation, thereby leading to increased production of prostaglandins, is also augmenting the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, naproxen, ketoprofen, etc., for relieving menstrual cramps as well as reducing inflammation is creating a positive outlook for the market. Apart from this, the escalating usage of hormonal contraceptives, including birth control pills, rings, patches, etc., to help regulate the menstrual cycle and lower the severity of dysmenorrhea symptoms is acting as another significant growth-inducing factor. Additionally, various key players are making extensive investments in research activities to develop drugs that block the formation of prostaglandins, which are hormone-like substances responsible for causing uterine contractions and pain during menstruation. This, in turn, is expected to drive the dysmenorrhea market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the dysmenorrhea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dysmenorrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysmenorrhea market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dysmenorrhea market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dysmenorrhea market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dysmenorrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the dysmenorrhea market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dysmenorrhea market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dysmenorrhea market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dysmenorrhea across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dysmenorrhea by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dysmenorrhea by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dysmenorrhea by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with dysmenorrhea across the seven major markets?
• What is the size of the dysmenorrhea patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dysmenorrhea?
• What will be the growth rate of patients across the seven major markets?
   

Dysmenorrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for dysmenorrhea drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dysmenorrhea market?
• What are the key regulatory events related to the dysmenorrhea market?
• What is the structure of clinical trial landscape by status related to the dysmenorrhea market?
• What is the structure of clinical trial landscape by phase related to the dysmenorrhea market?
• What is the structure of clinical trial landscape by route of administration related to the dysmenorrhea market?